A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Oncology

• Publication date

  2016-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2016.34.15_SUPPL.9013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)

  2022cites this paper
• RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

  2020cites this paper
• RET rearrangements are actionable alterations in breast cancer

  2018cites this paper
• New Targets in Non-Small Cell Lung Cancer.

  2017cites this paper
• Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016.

  2017cites this paper
• Targeted therapy outcomes in RET-rearranged lung cancers: drug or driver?

  2017cites this paper
• 晚期非小细胞肺癌靶向治疗进展与展望：聚焦小分子酪氨酸激酶抑制剂

  2017cites this paper
• Molecular biomarkers for lung adenocarcinoma

  2017cites this paper
• Molecular Targets in Non-Small Cell Lung Cancer.

  2017cites this paper
• Biological therapies in nonsmall cell lung cancer

  2017cites this paper
• Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.

  2017cites this paper
• Lung Cancer Management: where are we in 2017?

  2017cites this paper
• Scientific Advances in Thoracic Oncology 2016.

  2017cites this paper
• A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers

  2016cites this paper
• New and emerging targeted treatments in advanced non-small-cell lung cancer.

  2016cites this paper
• Clinical Activity of Alectinib in Advanced RET‐Rearranged Non–Small Cell Lung Cancer

  2016cites this paper
• Best Practices in Treatment Selection for Patients With Advanced NSCLC.

  2016cites this paper
• Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations

  2016cites this paper
• A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers

  2016cites this paper
• NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer

  2014cites this paper